Efficacy and Safety of Lebrikizumab in moderate to severe atopic Dermatitis: Results of two randomized, double-blind, placebo-controlled phase III Studies (ADvocate1 and ADvocate2) at 52 Weeks

被引：0
|
作者：
Blauvelt, A. [1 ]
Thyssen, J. P. [2 ]
Guttman-Yassky, E. [3 ]
Bieber, T. [4 ]
Serra-Baldrich, E. [5 ]
Simspon, E. [6 ]
Rosmarin, D. [7 ]
Diemert, S. [8 ]
Elmaraghy, H. [9 ]
Silverberg, J. [10 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Univ Copenhagen, Bispebjerg Hosp, Copenhagen, Denmark
[3] Icahn Sch Med Mt Sinai, New York, NY USA
[4] Univ Hosp Bonn, Bonn, Germany
[5] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[6] Oregon Hlth & Sci Univ, Portland, OR USA
[7] Tufts Univ, Sch Med, Boston, MA USA
[8] Almirall Hermal GmbH, Reinbek, Germany
[9] Eli Lilly & Co, Indianapolis, IN USA
[10] George Washington Univ, Sch Med & Hlth Sci, Washington, OR USA
来源：
ALLERGOLOGIE | 2023年 / 46卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P4.01
引用
收藏
页码：530 / 530
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of CM310 in moderate to severe asthma: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
    Su, Nan
    Zhang, Ling
    Peng, Liping
    Jiang, Yi
    Li, Jie
    Lin, Changqing
    Gao, Junzhen
    Chen, Zhihong
    Xiao, Zuke
    Zhang, Dong
    Wu, Haihong
    Wang, Shengyu
    Wang, Zaiyi
    Zhang, Xiangjie
    Qi, Xiaomeng
    Qiu, Jingbo
    Wang, Wenjuan
    Xiang, Anbo
    Li, Chunle
    Wang, Chen
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [42] EFFICACY AND SAFETY OF DUPILUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN CHINESE ADULTS: A MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL
    Zhao, Yan
    Wu, Liming
    Lu, Qianjin
    Gao, Xinghua
    Zhu, Xiaohong
    Yao, Xu
    Li, Linfeng
    Li, Wei
    Ding, Yangfeng
    Song, Zhiqiang
    Liu, Lingling
    Dang, Ningning
    Zhang, Chunlei
    Liu, Xiaoming
    Gu, Jun
    Wang, Jinyan
    Geng, Songhai
    Liu, Qunazhong
    Guo, Yifeng
    Lv, Dong
    Ren, Gong
    Yang, Xiumin
    Deng, Danqi
    Li, Shanshan
    Han, Xiuping
    Biao, Shuzhen
    Zheng, Min
    Dong, Li
    Su, Huijuan
    Bai, Lili
    O'Malley, John T.
    Luo, Junxiang
    Zhang, Jianzhong
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 58 - 58
  • [43] Dupilumab pharmacokinetics in Chinese healthy subjects and patients with atopic dermatitis: Results of two randomized, double-blind, placebo-controlled studies
    Clot, Pierre-Francois
    Kamal, Mohamed
    Sun, Jing
    Xu, Christine
    Kong, Fangyuan
    Gu, Yongzhen
    Yang, Na
    Yin, WeiHong
    Chen, Bing
    Ming, Jeffrey E.
    Yuan, Yaozong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 99
  • [44] Efficacy of Probiotics in Children and Adolescents With Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Study
    Andrade, Paula Danielle Santa Maria Albuquerque de
    Silva, Jorgete
    Carregaro, Vanessa
    Sacramento, Lais Amorim
    Roberti, Luciana Rodrigues
    Aragon, Davi Casale
    Carmona, Fabio
    Roxo-Junior, Persio
    FRONTIERS IN NUTRITION, 2022, 8
  • [45] Efficacy of Probiotic Therapy on Atopic Dermatitis in Children: A Randomized, Double-blind, Placebo-controlled Trial
    Yang, Hyeon-Jong
    Min, Taek Ki
    Lee, Hae Won
    Pyun, Bok Yang
    ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2014, 6 (03) : 208 - 215
  • [46] A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Talactoferrin in Patients With Severe Sepsis
    Guntupalli, Kalpalatha
    Dean, Nathan
    Morris, Peter E.
    Bandi, Venkata
    Margolis, Benjamin
    Rivers, Emanuel
    Levy, Mitchell
    Lodato, Robert F.
    Ismail, Preeti M.
    Reese, Amber
    Schaumberg, John P.
    Malik, Rajesh
    Dellinger, R. Phillip
    CRITICAL CARE MEDICINE, 2013, 41 (03) : 706 - 716
  • [47] Results from a phase IIa randomized, double-blind, placebo-controlled, exploratory, multicentre study of GBR 830 in adults with moderate-to-severe atopic dermatitis
    Guttman-Yassky, E.
    Pavel, A.
    Estrada, Y.
    Zhang, N.
    Peng, X.
    Xu, H.
    Wen, H.
    Fang, H.
    Salhi, Y.
    Gudi, G.
    Ca, V.
    Gn, S.
    Grossman, F.
    Wolff, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (01) : E44 - E45
  • [48] Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
    Inman, Robert D.
    Davis, John C., Jr.
    van der Heijde, Desiree
    Dickman, Laura
    Sieper, Joachim
    Kim, Sung Il
    Mack, Michael
    Han, John
    Visvanathan, Sudha
    Xu, Zhenhua
    Su, Benjamin
    Beutler, Anna
    Braun, Juergen
    ARTHRITIS AND RHEUMATISM, 2008, 58 (11): : 3402 - 3412
  • [49] Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-MorbiditiesSubanalysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
    Alexa B. Kimball
    Arielle G. Bensimon
    Annie Guerin
    Andrew P. Yu
    Eric Q. Wu
    Martin M. Okun
    Yanjun Bao
    Shiraz R. Gupta
    Parvez M. Mulani
    American Journal of Clinical Dermatology, 2011, 12 : 51 - 62
  • [50] Efficacy and Safety of Brodalumab In Patients With Moderate To Severe Plaque Psoriasis: Results of AMAGINE-1, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
    Papp, K.
    Reich, K.
    Blauvelt, A.
    Baran, W.
    Bolduc, C.
    Toth, D.
    Gottlieb, A. B.
    Thaci, D.
    Li, J.
    Nirula, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S8 - S8
12345